1.
Meletios A. Dimopoulos, Meral Beksac, Lotfi Benboubker, Huw Roddie, Nathalie Allietta, Esther Broer, Catherine Couturier, Marie-Andrée Mazier, Ralf Angermund, Thierry Facon. Phase II study of bortezomib–dexamethasone alone or with added cyclophosphamide or lenalidomide for sub-optimal response as second-line treatment for patients with multiple myeloma. haematol [Internet]. 2013Jul.31 [cited 2024Jul.24];98(8):1264-72. Available from: https://haematologica.org/article/view/6753